Reference Product INTUNIV XR (Takeda)

# **JAMP Guanfacine XR**RX Products



# **AVAILABLE NOW!**











**Actual size JAMP** 



Actual size Reference Product

DIN

02523558

**UPC Code** 





**Actual size JAMP** 






Actual size Reference Product



**Actual size JAMP** 





3 mg • Bo 100





Actual size JAMP





Actual size Reference Product

1 mg ⋅ Bo 100 2 mg ⋅ Bo 100

DIN 02523566

**UPC Code** 

**DIN** 02523574 4 mg • Bo 100

02523582

**UPC Code** 

6 22082 29629 6

**UPC Code** 



For more information, please contact your local JAMP Pharma representative, send us a message at **custjamp@jamppharma.com** or call us at **1-866-399-9091**.

(For visual comparison only)






## **PATIENT MONITORING TOOLS**

**Attention-deficit/hyperactivity disorder (ADHD)** 

### Bioequivalence curve - after meal\*



- 1: JAMP Guanfacine XR (guanfacine hydrochloride) extended release tablet, 4 mg (JAMP Pharma Corporation)
- 2: INTUNIV XR® (guanfacine hydrochloride) extended release tablet, 4 mg (Shire Pharma Canada ULC)
- 3: Expressed as the median (range) only
- 4: Expressed as the arithmetic mean (CV%) only

\*https://pdf.hres.ca/dpd\_pm/00064193.PDF

#### "DATER" Diagram - CADDRA

The "DATER" diagram is a tool from CADDRA - Canadian ADHD Resource Alliance assisting the evaluation of a treatment for ADHD. It will contribute, through its methodology, to confirm that the treatment is appropriate for the patient.

Table 5.9 Facts to Consider Prior to Making Medication Changes

D	<b>Dosage</b> - Has the medication been tried on a high enough dose, is the duration of effect adequate? Side effects: Is the dosage too low or too high?
A	<b>All</b> - Have all medications within the higher line(s) of treatment (when clinically indicated and reasonable) been attempted? If not, explore why.
т	<b>Time</b> - Has enough time been given to examine patient response and for side effects to resolve?
Е	<b>Examine</b> - Has the patient-doctor team determined specific targets for treatment and means to measure changes? Select standardized measures to examine response and plan examination of response from many perspectives (e.g., teacher, parent, spouse and self-report).
R	<b>Review</b> - Has the diagnostic process reviewed potential comorbidity, psychosocial complications and lifestyle issues?

Table reproduced with permission from CADDRA - Canadian ADHD Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition, Toronto, ON; CADDRA, 2020.



